These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21840145)

  • 1. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
    Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
    Reis M; Lundmark J; Björk H; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
    Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
    Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
    Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
    Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
    Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
    Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexed quantification of venlafaxine and metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Pandey A; Price A; Ayala-Lopez N; Garza KY; Marzinke MA; Knezevic CE
    J Pharm Biomed Anal; 2024 Jun; 243():116082. PubMed ID: 38461636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
    Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
    J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients.
    Godoy AL; Rocha A; da Silva Souza C; Lanchote VL
    J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
    Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
    J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
    Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection.
    Vu RL; Helmeste D; Albers L; Reist C
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):195-201. PubMed ID: 9448076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
    Murrell MD; Cruz DA; Javors MA; Thompson PM
    J Forensic Sci; 2014 May; 59(3):683-9. PubMed ID: 24502274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
    Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
    Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry.
    Miranda LF; Domingues DS; Queiroz ME
    J Chromatogr A; 2016 Aug; 1458():46-53. PubMed ID: 27388659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
    Launiainen T; Rasanen I; Vuori E; Ojanperä I
    Int J Legal Med; 2011 May; 125(3):349-58. PubMed ID: 20432045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.